UCB SA (OTCMKTS:UCBJF – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $195.88 and last traded at $195.88, with a volume of 87 shares trading hands. The stock had previously closed at $174.00.
UCB Trading Up 0.0 %
The firm has a fifty day simple moving average of $180.30 and a 200 day simple moving average of $164.98. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- How to trade using analyst ratings
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- Trading Stocks: RSI and Why it’s Useful
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
